CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops
TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
"At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia."
Why XRP? Why Now?
We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others:
Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.Scope: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.
These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.
Use Cases Across the Ecosystem
Real-time settlement between pharmacies, suppliers, and manufacturersSmart rebates calculated automatically based on real-world dataXRP-backed credit lines to enhance liquidity for independent pharmaciesGlobal vendor payouts with near-zero foreign transaction and wire costsImmutable compliance layer supporting DSCSA reporting and pricing validation
"We're working to unlock capital velocity with surgical precision," said Mark DiSiena, CFO of Wellgistics Health. "We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure."
The Market Is Moving-And Wellgistics Intends to Lead
XRP is gaining momentum across global institutions, as demonstrated by the following:
CME Group to launch XRP futures for institutional access→ CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹Mastercard identifies XRP as a bridge currency for cross-border payments→ Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²Ripple acquires prime brokerage firm Hidden Road for $1.25B→ This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³Ripple receives regulatory licensing in Dubai→ Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴Ripple expands real-world cross-border payment corridors in Brazil and Portugal→ Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵
"Others are waiting for change. We're building it," Norton added. "I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge."
About Wellgistics Health
Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide.
Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients.
For more information, visit: www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
Media Contact: media@wellgisticshealth.comInvestor Relations: investors@wellgisticshealth.com
References
CME Group Press Release: CME to Launch XRP FuturesAInvest: Mastercard Identifies XRP as Bridge CurrencyReuters: Ripple Acquires Hidden Road for $1.25BBusinessWire: Ripple Licensed by DFSA in DubaiPYMNTS: Ripple Launches Portugal-Brazil Corridor
SOURCE: Wellgistics Health, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency
Roper Technologies, Inc. (NASDAQ:ROP) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. A software developer looking out a window while confidently typing away on their laptop. Roper Technologies, Inc. (NASDAQ:ROP) is a group of technology businesses that hold strong positions in specialized niche markets. Its portfolio includes application software, network software, and technology-enabled products, all designed to deliver essential solutions that become deeply integrated into customers' operations. These offerings typically lead to high switching costs and generate steady, recurring revenue. In the second quarter of 2025, Roper Technologies, Inc. (NASDAQ:ROP) reported a 13.2% increase in revenue, driven by 7% organic growth and a 6% boost from recent acquisitions. GAAP net earnings rose by 12%. Management pointed to balanced growth across all major segments, crediting strong product innovation, successful integration of past acquisitions, and ongoing demand for recurring software solutions. Roper Technologies, Inc. (NASDAQ:ROP) has garnered investor attention because the company has a strong dividend policy. On June 11, the company declared a quarterly dividend of $0.825 per share, which was in line with its previous dividend. Overall, it has raised its payouts for 33 consecutive years, which makes ROP one of the best dividend stocks to buy and hold. The stock has a dividend yield of 0.60%, as of July 31. While we acknowledge the potential of ROP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
32 minutes ago
- Forbes
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements. The median positive return has been 3.0%, with a maximum one-day increase of 9.0%. For those trading based on events, recognizing these historical trends can prove advantageous, although actual performance against expectations will be crucial. There are two primary strategies to think about: Analysts anticipate Vertex will disclose earnings of $4.25 per share, generating a revenue of $2.91 billion. This marks a considerable improvement compared to the same quarter last year, which reported a loss of $12.83 per share on sales of $2.65 billion. However, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. View earnings reaction history of all stocks Vertex Pharmaceuticals' Historical Probability of Positive Post-Earnings Return Some insights regarding one-day (1D) post-earnings returns: Further information on observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized in the table below along with the related statistics. Correlation Between 1D, 5D and 21D Historical Returns A comparatively lower-risk approach (though not effective if the correlation is weak) is to evaluate the correlation between short-term and medium-term returns after earnings, identify the pair that exhibits the strongest correlation, and perform the proper trade. For instance, if 1D and 5D display the highest correlation, a trader can place themselves "long" for the forthcoming 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on both a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D indicates the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (the combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for stakeholders. Additionally, if you're seeking upside with a more stable journey than an individual stock like Vertex Pharmaceuticals, think about the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception.
Business Insider
an hour ago
- Business Insider
Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity
In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Alphatec Holdings, with a price target of $20.00. The company's shares closed today at $13.77. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cronin is a 2-star analyst with an average return of 0.5% and a 45.74% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Vericel, and Orthofix. In addition to Canaccord Genuity, Alphatec Holdings also received a Buy from Lake Street's Ben Haynor in a report issued today. However, on July 30, TR | OpenAI – 4o reiterated a Hold rating on Alphatec Holdings (NASDAQ: ATEC). Based on Alphatec Holdings' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $169.18 million and a GAAP net loss of $51.91 million. In comparison, last year the company earned a revenue of $138.48 million and had a GAAP net loss of $48.5 million Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year. Most recently, in May 2025, Scott Lish, the COO of ATEC sold 12,000.00 shares for a total of $145,440.00.
